MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States.
Excellent balance sheet with limited growth.
Share Price & News
How has MacroGenics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MGNX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MGNX exceeded the US Biotechs industry which returned 23.6% over the past year.
Return vs Market: MGNX exceeded the US Market which returned 4.1% over the past year.
Price Volatility Vs. Market
How volatile is MacroGenics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWhat You Need To Know About The MacroGenics, Inc. (NASDAQ:MGNX) Analyst Downgrade Today
4 weeks ago | Simply Wall StEasy Come, Easy Go: How MacroGenics (NASDAQ:MGNX) Shareholders Got Unlucky And Saw 72% Of Their Cash Evaporate
2 months ago | Simply Wall StDoes MacroGenics, Inc.'s (NASDAQ:MGNX) CEO Pay Compare Well With Peers?
Is MacroGenics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: MGNX ($25.37) is trading above our estimate of fair value ($5.07)
Significantly Below Fair Value: MGNX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MGNX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MGNX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MGNX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MGNX is overvalued based on its PB Ratio (6.5x) compared to the US Biotechs industry average (3.8x).
How is MacroGenics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MGNX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MGNX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MGNX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MGNX's revenue (22.2% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: MGNX's revenue (22.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MGNX is forecast to be unprofitable in 3 years.
How has MacroGenics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MGNX is currently unprofitable.
Growing Profit Margin: MGNX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MGNX is unprofitable, and losses have increased over the past 5 years at a rate of -37.3% per year.
Accelerating Growth: Unable to compare MGNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MGNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: MGNX has a negative Return on Equity (-79.51%), as it is currently unprofitable.
How is MacroGenics's financial position?
Financial Position Analysis
Short Term Liabilities: MGNX's short term assets ($195.3M) exceed its short term liabilities ($39.6M).
Long Term Liabilities: MGNX's short term assets ($195.3M) exceed its long term liabilities ($35.2M).
Debt to Equity History and Analysis
Debt Level: MGNX is debt free.
Reducing Debt: MGNX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MGNX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MGNX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 33.8% each year
What is MacroGenics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MGNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MGNX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MGNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Scott Koenig (67yo)
Dr. Scott Koenig, M.D., Ph.D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig served as Senior Vice President of Research at MedImmune Inc., where ...
CEO Compensation Analysis
Compensation vs Market: Scott's total compensation ($USD4.72M) is about average for companies of similar size in the US market ($USD4.91M).
Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.
|CEO, President & Director||18.67yrs||US$4.72m||2.37% $29.5m|
|Senior VP||12yrs||US$1.78m||0.31% $3.9m|
|Senior VP of Research||3.67yrs||US$1.90m||0.31% $3.9m|
|Senior VP of Business Development & Portfolio Management and Chief Business Officer||3.67yrs||US$1.78m||0.090% $1.1m|
|Vice President of Investor Relations & Corporate Communications||no data||no data||no data|
|VP & General Counsel||2.92yrs||no data||0.00041% $5.1k|
|Senior Vice President of BioPharmaceutical Development & Manufacturing||no data||no data||no data|
|VP, Controller & Treasurer||16.58yrs||no data||no data|
Experienced Management: MGNX's management team is seasoned and experienced (7.8 years average tenure).
|CEO, President & Director||18.67yrs||US$4.72m||2.37% $29.5m|
|Independent Director||6.67yrs||US$176.53k||no data|
|Independent Director||15.58yrs||US$171.50k||0.037% $458.5k|
|Independent Director||11.83yrs||US$187.47k||0.095% $1.2m|
|Independent Chairman of the Board||6.67yrs||US$210.46k||0.12% $1.5m|
|Independent Director||3.33yrs||US$175.47k||no data|
|Independent Director||2.5yrs||US$180.12k||no data|
|Independent Director||3.33yrs||US$176.53k||no data|
Experienced Board: MGNX's board of directors are considered experienced (6.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
MacroGenics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: MacroGenics, Inc.
- Ticker: MGNX
- Exchange: NasdaqGS
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.247b
- Shares outstanding: 49.14m
- Website: https://www.macrogenics.com
Number of Employees
- MacroGenics, Inc.
- 9704 Medical Center Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MGNX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Oct 2013|
|M55||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2013|
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targeting PD-1; MGD013, a monoclonal antibody that targets the PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing combination of MGD009 and MGA012; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD014, a DART molecule that targets envelope protein of human immunodeficiency virus infected cells and T cells. It has strategic collaborations with Incyte Corporation; Zai Lab Limited; and I-Mab Biopharma. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/26 05:38|
|End of Day Share Price||2020/05/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.